Do analysts recommend MGRX or CCM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, MGRX or CCM?

Concord Medical Services has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 12.95 -$20.64M -$1.49 N/A Concord Medical Services $65.85M 0.30 -$13.27M N/A N/A

Do analysts prefer MRAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or MGRX more profitable?

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Mangoceuticals -4,639.13% -112.00% -104.96%

Do analysts prefer MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $460K 12.95 -$20.64M -$1.49 N/A Basel Medical Group $8.90M 1.21 -$9.50M N/A N/A

Do analysts rate BRTX or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ACON or MGRX?

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 159.52%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts clearly believe Aclarion is more favorable than Mangoceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACON or MGRX more profitable?

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aclarion -10,320.51% -54.41% -51.71% Mangoceuticals -4,639.13% -112.00% -104.96%

Mangoceuticals (MGRX) Competitors

$0.35 +0.06 (+19.24%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$0.34 0.00 (-1.15%)

As of 04:44 AM Eastern

Compare

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

Should you buy Mangoceuticals stock or one of its competitors? MarketBeat compares Mangoceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mangoceuticals include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Biorestorative Therapies (BRTX), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Mangoceuticals compare to Concord Medical Services?

Mangoceuticals (NASDAQ:MGRX) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Mangoceuticals has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Concord Medical Services has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Concord Medical Services' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Concord Medical Services	N/A	N/A	N/A

In the previous week, Mangoceuticals' average media sentiment score of 0.00 equaled Concord Medical Services'average media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
Concord Medical Services	Neutral

Concord Medical Services has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A
Concord Medical Services	$65.85M	0.30	-$13.27M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Comparatively, 46.5% of Concord Medical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Concord Medical Services beats Mangoceuticals on 6 of the 9 factors compared between the two stocks.

How does Mangoceuticals compare to Marpai?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Marpai had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Mangoceuticals. Marpai's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Marpai	Neutral
Mangoceuticals	Neutral

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.49	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

49.8% of Marpai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Marpai beats Mangoceuticals on 8 of the 13 factors compared between the two stocks.

How does Mangoceuticals compare to Basel Medical Group?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Mangoceuticals has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Basel Medical Group	N/A	N/A	N/A

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Basel Medical Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Mangoceuticals	Neutral
Basel Medical Group	Neutral

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A
Basel Medical Group	$8.90M	1.21	-$9.50M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 10 factors compared between the two stocks.

How does Mangoceuticals compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Biorestorative Therapies has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market.

Biorestorative Therapies has a net margin of -3,088.27% compared to Mangoceuticals' net margin of -4,639.13%. Mangoceuticals' return on equity of -112.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Biorestorative Therapies has higher earnings, but lower revenue than Mangoceuticals. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	27.54	-$14.24M	-$1.07	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Biorestorative Therapies and 0 mentions for Mangoceuticals. Biorestorative Therapies' average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Mangoceuticals	Neutral

Summary

Biorestorative Therapies and Mangoceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Mangoceuticals compare to Aclarion?

Aclarion (NASDAQ:ACON) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Aclarion has higher earnings, but lower revenue than Mangoceuticals. Aclarion is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	88.87	-$7.23M	-$9.03	N/A
Mangoceuticals	$460K	12.95	-$20.64M	-$1.49	N/A

In the previous week, Aclarion had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Mangoceuticals. Aclarion's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company	Overall Sentiment
Aclarion	Neutral
Mangoceuticals	Neutral

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 159.52%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts clearly believe Aclarion is more favorable than Mangoceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.5% of Aclarion shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mangoceuticals has a net margin of -4,639.13% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Aclarion has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

Summary

Aclarion beats Mangoceuticals on 8 of the 15 factors compared between the two stocks.

Get Mangoceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGRX vs. The Competition

Export

Metric	Mangoceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.23	18.43	24.67	23.99
Price / Sales	12.95	326.44	528.41	106.93
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	0.37	4.11	10.76	6.50
Net Income	-$20.64M	$64.45M	$3.56B	$336.88M
7 Day Performance	4.49%	1.41%	1.03%	-0.14%
1 Month Performance	-23.06%	1.04%	0.45%	0.77%
1 Year Performance	-82.82%	23.88%	29.69%	28.49%

Mangoceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGRX Mangoceuticals	0.918 of 5 stars	$0.35 +19.2%	N/A	-81.3%	$5M	$460K	N/A	3	High Trading Volume
CCM Concord Medical Services	0.4416 of 5 stars	$4.59 +1.1%	N/A	-21.4%	$19.92M	$65.85M	N/A	970
MRAI Marpai	N/A	$0.55 +6.8%	N/A	-49.1%	$14.12M	$34.87M	N/A	150	Gap Down
BMGL Basel Medical Group	0.7148 of 5 stars	$0.56 -3.7%	N/A	-76.0%	$11.22M	$11.32M	N/A	36	Gap Down
BRTX Biorestorative Therapies	0.4273 of 5 stars	$0.37 -2.7%	N/A	-76.3%	$9.33M	$360K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Summary

How does Mangoceuticals compare to Marpai?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Summary

How does Mangoceuticals compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mangoceuticals (MGRX) Competitors

MGRX vs. CCM, MRAI, BMGL, BRTX, and ACON

How does Mangoceuticals compare to Concord Medical Services?

Which has more volatility & risk, MGRX or CCM?

Is MGRX or CCM more profitable?

Does the media favor MGRX or CCM?

Which has better valuation & earnings, MGRX or CCM?

Do analysts recommend MGRX or CCM?

Do institutionals & insiders have more ownership in MGRX or CCM?

Summary

How does Mangoceuticals compare to Marpai?

Do analysts prefer MRAI or MGRX?

Does the media refer more to MRAI or MGRX?

Which has better valuation and earnings, MRAI or MGRX?

Which has more risk and volatility, MRAI or MGRX?

Is MRAI or MGRX more profitable?

Do institutionals and insiders hold more shares of MRAI or MGRX?

Summary

How does Mangoceuticals compare to Basel Medical Group?

Which has more risk and volatility, MGRX or BMGL?

Is MGRX or BMGL more profitable?

Do institutionals & insiders believe in MGRX or BMGL?

Does the media prefer MGRX or BMGL?

Which has stronger valuation and earnings, MGRX or BMGL?

Do analysts prefer MGRX or BMGL?

Summary

How does Mangoceuticals compare to Biorestorative Therapies?

Which has more risk & volatility, BRTX or MGRX?

Is BRTX or MGRX more profitable?

Which has stronger valuation and earnings, BRTX or MGRX?

Do analysts rate BRTX or MGRX?

Do institutionals & insiders believe in BRTX or MGRX?

Does the media refer more to BRTX or MGRX?

Summary

How does Mangoceuticals compare to Aclarion?

Which has preferable valuation & earnings, ACON or MGRX?

Does the media refer more to ACON or MGRX?

Do analysts recommend ACON or MGRX?

Do insiders & institutionals have more ownership in ACON or MGRX?

Is ACON or MGRX more profitable?

Which has more volatility & risk, ACON or MGRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGRX vs. The Competition

Mangoceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools